Down-regulation of miR-199b associated with imatinib drug resistance in 9q34.1 deleted BCR/ABL positive CML patients

Gene

Volumn 542, Issue 2, 2014, Pages 109-112

  Joshi, Dolly ^a   Chandrakala, S ^b   Korgaonkar, Seema ^a   Ghosh, Kanjaksha ^a   Vundinti, Babu Rao ^a  

^a NATIONAL INSTITUTE OF IMMUNOHAEMATOLOGY   (India)

^b KEM HOSPITAL   (India)

Author keywords

9q deletion; Chronic myeloid leukemia; MiR 199b; MiR 219 2; Real time PCR

Indexed keywords

9Q DELETION; CHRONIC MYELOID LEUKEMIA; MIR-199B; MIR-219-2; REAL TIME PCR;

ADOLESCENT; ADULT; AGED; BENZAMIDES; CHILD; CHILD, PRESCHOOL; CHROMOSOME DELETION; CHROMOSOMES, ARTIFICIAL, BACTERIAL; CHROMOSOMES, HUMAN, PAIR 9; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MICRORNAS; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; YOUNG ADULT;

EID: 84898782111     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2014.03.049     Document Type: Article

References (29)

1. Agirre X., Jimenez-Velasco A., San Jose-Eneriz E., et al. Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth. Molecular Cancer Research 2008, 6:1830-1840.
2. Albano F., Anelli L., Zagaria A., et al. MIRN 199B downregulation in chronic myeloid leukaemia is associated with deletions on der (9). British Journal of Haematology 2008, 144:263-275.
3. Baccarani M., Cortes J., Pane F., Niederwieser D., Saglio G., Apperley J., et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. Journal of Clinical Oncology 2009, 27(35):6041-6051.
4. Bartram C.R., de Klein A., Hagemeijer A., et al. Translocation of the c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelotic leukemia. Nature 1983, 306:277-280.
5. Beran M., Cao X., Estrov Z., et al. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clinical Cancer Research 1998, 4:1661-1672.
6. Calin G.A., Calin D.D., Shimizu M., et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. PNAS 2002, 26:15524-15529.
7. Chaubey A., Karanti S., Rai D., et al. MicroRNAs and deletion of the derivative chromosome 9 in chronic myeloid leukemia. Leukemia Advance 2008, 154.
8. Chen C.h.Z., Li L., Lodish H.F., Bartel D.P. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004, 303:83-86.
9. Cohen N., Rozenfeld-Granot G., Hardan I., et al. Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by a deletion of 9q proximal to ABL gene: expression profiling, resistance to interferon therapy, and poor prognosis. Cancer Genetics and Cytogenetics 2001, 128:114-119.
10. Druker B.J., Tamura S., Buchdunger E., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Medicine 1996, 2:561-566.
11. Eneriz E.S.J., Román-Gómez J., Jiménez-Velasco A., et al. MicroRNA expression profiling in imatinib-resistant chronic myeloid leukemia patients without clinically significant ABLI-mutations. Molecular Cancer 2009, 8:69-72.
12. Flamant S., Richie W., Guilhot J., et al. Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia. Haematologica 2010, 95:1325-1333.
13. Garzon R., Fabbri M., Cimmino A., et al. MicroRNA expression and function in cancer. Trends in Molecular Medicine 2006, 12(12):580-587. (Review).
14. Garzon R., Calin G.A., Croce C.M. MicroRNAs in cancer. Annual Review of Medicine 2009, 60:167-179.
15. Griffiths J.S., Saini H.K., van Dongen S., et al. miRBase: tools for microRNA genomics. Nucleic Acids Research 2008, 36:D154-D158.
16. Huntley B.J., Reid A.G., Bench A.J., et al. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 2001, 98:1732-1738.
17. Huntley B.J., Bench A.J., Delabesse E., et al. Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability. Blood 2002, 99:4547-4553.
18. Huntley B.J., Bench A., Green A.R. Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia. Blood 2003, 102(4):1160-1168.
19. Loncarevic I.F., Romer J., Starke H., et al. Heterogenic molecular basis for loss of ABL1-BCR transcription: deletions in der(9)t(9;22) and variants of standard t(9;22) in BCR-ABL1-positive chronic myeloid leukemia. Genes, Chromosomes & Cancer 2002, 34:193-200.
20. Moorhead P.S., Nowell P.C., Mellman W.J., et al. Hungerford: chromosome preparations of leucocytes cultures from human peripheral blood. Experimental Cell Research 1960, 20:613-616.
21. Nederlof P.M., Robinson D., Auknesha R., et al. Three color fluorescence in-situ hybridization for the simultaneous detection of multiple nucleic acid sequences. Cytometry 1989, 10:20-27.
22. Pfaffl M.W., Horgan G.W., Dempfle L. Relative Expression Software Tool (REST©) for group-wise comparison and statistical analysis of relative expression results in real time PCR. Nucleic Acids Research 2002, 30(9):1-10.
23. Rowley D.J. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giesma staining. Nature 1973, 243:290-293.
24. Shaffer L.G., Slovak M.L., Campbell L.J. ISCN 2009: An International System for Human Cytogenetic Nomenclature 2009, S. Karger AG, Basel.
25. Sinclair P.B., Nacheva E.P., Leversha M., et al. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 2000, 95:738-743.
26. Vaidya S., Ghosh K., Vundinti B.R. Recent developments in drug resistance mechanism in chronic myeloid leukemia: a review. European Journal of Haematology 2011, 87(5):381-393.
27. Venturini L., Battmer K., Castoldi M., et al. Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood 2007, 109:4399-4405.
28. Wang W.X., Kyprianou N., Wang X., et al. Dysregulation of the mitogen granulin in human cancer through the miR-15/107 microRNA gene group. Cancer Research 2010, 70:9137-9142.
29. Wilkinson K., Velloso E.R., Lopes L.F., Lee C., Aster J.C., Shipp M.A., Aguiar R.C. Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib. Blood 2003, 102(12):4187-4190.